Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Peter Dreger, MD, Andrea Schnaiter, MD, Marianna Rossi, Peter Paschka, Andreas Bühler, MD, Thorsten Zenz, MD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Donald Bunjes, Michael Stadler, MD, Lutz Uharek, MD, Christof Scheid, MD, PhD, Ute Hegenbart, MD, Michael Hallek, MD, Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2012) 120 (21): 966.

https://doi.org/10.1182/blood.V120.21.966.966

Published: 2012

Journal Articles

Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen

Kirsten Fischer, MD, Jasmin Bahlo, Anna- Maria Fink, MD, Raymonde Busch, Sebastian Böttcher, MD, Jiri Mayer, MD, Peter Dreger, MD, Christian Maurer, Anja Engelke, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Michael Hallek, MD

Blood (2012) 120 (21): 435.

https://doi.org/10.1182/blood.V120.21.435.435

Published: 2012

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network

Christiane Pott, Eva Hoster, Kheira Beldjord, Elizabeth A. Macintyre, Sebastian Böttcher, Vahid Asnafi, Reiner Siebert, Anne Plonquet, Evelyne Callet-Bauchut, Vincent Ribrag, Wolfram Klapper, Francoise Berger, Michael Unterhalt, Michael Kneba, Wolfgang Hiddemann, Martin H. Dreyling, Olivier Hermine, Marie-Helene Delfau

Blood (2010) 116 (21): 965.

https://doi.org/10.1182/blood.V116.21.965.965

Published: 2010

Journal Articles

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

Thorsten Zenz, MD, Peter Dreger, MD, PhD, Sascha Dietrich, MD, Sebastian Böttcher, MD, Matthias Ritgen, MD, Dirk Winkler, MD, Andreas Bühler, MD, Donald Bunjes, MD, Dietrich Beelen, MD, Sandra Cohen, MD, FRCPC, Ute Hegenbart, MD, Matthias Zeis, MD, Michael Hallek, M.D., Michael Kneba, MD, PhD, Norbert Schmitz, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, M.D.

Blood (2010) 116 (21): 2357.

https://doi.org/10.1182/blood.V116.21.2357.2357

Published: 2010

Journal Articles

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

Blood (2009) 114 (22): 1267.

https://doi.org/10.1182/blood.V114.22.1267.1267

Published: 2009

Journal Articles

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Kirsten Fischer, MD, Stephan Stilgenbauer, MD, Carmen D Schweighofer, MD, Raymonde Busch, Jasmin Renschler, Michael Kiehl, MD, Leopold Balleisen, MD, Michael J Eckart, MD, Anna- Maria Fink, MD, Julia Kilp, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Michael Kneba, MD, PhD, Hartmut Döhner, MD, Barbara F Eichhorst, MD, Michael Hallek, MD, Clemens- Martin Wendtner, MD, The German CLL Study Group

Blood (2008) 112 (11): 330.

https://doi.org/10.1182/blood.V112.11.330.330

Published: 2008

Journal Articles

Molecular Remission after Combined Immunochemotherapy Is of Prognostic Relevance in Patients with MCL: Results of the Randomized Intergroup Trials of the European MCL Network

Christiane Pott, Eva Hoster, Sebastian Böttcher, Reiner Siebert, Wolfram Klapper, Marie Helene Delfau, Michael Unterhalt, Wolfgang Hiddemann, Michael Kneba, Martin Dreyling

Blood (2008) 112 (11): 582.

https://doi.org/10.1182/blood.V112.11.582.582

Published: 2008

Journal Articles

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Raymonde Busch, Günther Fingerle-Rowson, Kirsten Fischer, Anna- Maria Fink, Ulrich Jäger, Sebastian Böttcher, Michael Kneba, Michael Wenger, Myriam Mendila, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 781.

https://doi.org/10.1182/blood.V112.11.781.781

Published: 2008

Journal Articles

Flow Cytometric Detection of BCR-ABL Fusion Proteins in Leukemia Patients Via An Immunobead Assay

Floor Weerkamp, E. Dekking, Vincent H.J. Van der Velden, Sebastian Böttcher, Nancy Boeckx, Elisabeth R. Van Wering, Juan Flores Montero, Paulo Lucio, Lukasz Sedek, Tomas Kalina, Elizabeth Macintyre, Frank J.T. Staal, Jacques JM van Dongen, Ph.D

Blood (2008) 112 (11): 2533.

https://doi.org/10.1182/blood.V112.11.2533.2533

Published: 2008

Journal Articles

MRD Kinetics in Adult Transplantation Recipients with Relapsed Acute Lymphoblastic Leukemia Depend on Initial Molecular Response to Front-Line Chemotherapy.

Monika Brüggemann, MD, Thorsten Raff, MD, Christiane Pott, MD, Sebastian Böttcher, MD, Matthias Ritgen, MD, Renate Arnold, MD, Dieter Hoelzer, MD, Nicola Goekbuget, MD, Michael Kneba, MD

Blood (2007) 110 (11): 2799.

https://doi.org/10.1182/blood.V110.11.2799.2799

Published: 2007

Journal Articles

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

Thorsten Raff, Nicola Gökbuget, Silke Lüschen, Regina Reutzel, Matthias Ritgen, Sebastian Irmer, Sebastian Böttcher, Heinz-August Horst, Michael Kneba, Dieter Hoelzer, Monika Brüggemann, for the GMALL Study Group

Blood (2006) 109 (3): 910–915.

https://doi.org/10.1182/blood-2006-07-037093

Published: 2006

Journal Articles

Autologous graft-versus-host disease–like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia

Thorsten Zenz, Matthias Ritgen, Peter Dreger, Alexander Kröber, Thomas F. Barth, Richard Schlenk, Sebastian Böttcher, Michael J. Hallek, Michael Kneba, Donald Bunjes, Hartmut Döhner, Stephan Stilgenbauer

Blood (2006) 108 (6): 2127–2130.

https://doi.org/10.1182/blood-2006-04-007898

Published: 2006

Includes: Supplemental data

NARROW

SF3B1 , NOTCH1 and TP53 Mutations Do Not Affect the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 6-Year Follow-up of the Gcllsg CLL3X Trial

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network

Allogeneic Stem Cell Transplantation Can Overcome the Adverse Prognostic Impact of TP53 Mutation In Chronic Lymphocytic Leukemia (CLL): Results From the GCLLSG CLL3x Trial

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG)

Molecular Remission after Combined Immunochemotherapy Is of Prognostic Relevance in Patients with MCL: Results of the Randomized Intergroup Trials of the European MCL Network

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Flow Cytometric Detection of BCR-ABL Fusion Proteins in Leukemia Patients Via An Immunobead Assay

MRD Kinetics in Adult Transplantation Recipients with Relapsed Acute Lymphoblastic Leukemia Depend on Initial Molecular Response to Front-Line Chemotherapy.

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

Autologous graft-versus-host disease–like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only